Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Y Muller

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Advanced Drug Delivery Reviews|November 2, 2010
Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosingPatrick Y Muller
Expert Opinion on Drug Metabolism & Toxicology|July 21, 2009
Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoringPatrick Y Muller, Frank Dieterle
Atherosclerosis. Supplements|November 24, 2004
Large heterogeneity of mutations in the gene encoding the low-density lipoprotein receptor in subjects with familial hypercholesterolaemiaPatrick Y Muller, André R Miserez
Nature Reviews. Drug Discovery|September 1, 2012
The determination and interpretation of the therapeutic index in drug developmentPatrick Y Muller, Mark N Milton
AIDS (London, England)|August 13, 2002
Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activationsAndré R Miserez, Patrick Y Muller, Violeta Spaniol
Biotechniques|June 21, 2002
Processing of gene expression data generated by quantitative real-time RT-PCRPatrick Y Muller, Harald Janovjak, André R Miserez, et al.
Current Opinion in Biotechnology|November 10, 2009
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodiesPatrick Y Muller, Mark Milton, Peter Lloyd, et al.
Journal of Plant Physiology|July 13, 2005
Comparative quantification of pharmacodynamic parameters of chiral compounds (RRR- vs. all-rac-alpha tocopherol) by global gene expression profilingPatrick Y Muller, Thomas Netscher, Jan Frank, et al.
Cancer Genomics & Proteomics|August 10, 2019
Effect of Vitamin E on Cytochrome P450 mRNA Levels in Cultured Hepatocytes (HepG2) and in Rat LiverChristoph Hundhausen, Jan Frank, Gerald Rimbach, et al.
Drug Discovery Today|May 30, 2015
Integrated risk assessment of suicidal ideation and behavior in drug developmentPatrick Y Muller, Donna Dambach, Brian Gemzik, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Advanced Drug Delivery Reviews|November 2, 2010
Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosingPatrick Y Muller
Expert Opinion on Drug Metabolism & Toxicology|July 21, 2009
Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoringPatrick Y Muller, Frank Dieterle
Atherosclerosis. Supplements|November 24, 2004
Large heterogeneity of mutations in the gene encoding the low-density lipoprotein receptor in subjects with familial hypercholesterolaemiaPatrick Y Muller, André R Miserez
Nature Reviews. Drug Discovery|September 1, 2012
The determination and interpretation of the therapeutic index in drug developmentPatrick Y Muller, Mark N Milton
AIDS (London, England)|August 13, 2002
Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activationsAndré R Miserez, Patrick Y Muller, Violeta Spaniol
Biotechniques|June 21, 2002
Processing of gene expression data generated by quantitative real-time RT-PCRPatrick Y Muller, Harald Janovjak, André R Miserez, et al.
Current Opinion in Biotechnology|November 10, 2009
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodiesPatrick Y Muller, Mark Milton, Peter Lloyd, et al.
Journal of Plant Physiology|July 13, 2005
Comparative quantification of pharmacodynamic parameters of chiral compounds (RRR- vs. all-rac-alpha tocopherol) by global gene expression profilingPatrick Y Muller, Thomas Netscher, Jan Frank, et al.
Cancer Genomics & Proteomics|August 10, 2019
Effect of Vitamin E on Cytochrome P450 mRNA Levels in Cultured Hepatocytes (HepG2) and in Rat LiverChristoph Hundhausen, Jan Frank, Gerald Rimbach, et al.
Drug Discovery Today|May 30, 2015
Integrated risk assessment of suicidal ideation and behavior in drug developmentPatrick Y Muller, Donna Dambach, Brian Gemzik, et al.
Pageof 2